@FiercePharma: Few pharmas will profit off cardiovascular growth. Report | Follow @FiercePharma
> In a significant setback, Biogen Idec and Roche have suspended the troubled development program of ocrelizumab for rheumatoid arthritis, and analysts are already questioning if work related to multiple sclerosis may soon follow. Article
> AstraZeneca's cancer drug Recentin failed in a head to head late stage trial with Roche's Avastin in colorectal cancer patients, hurting the Anglo-Swedish drugmaker's shares on Monday. Recentin report
> Bulgaria's antitrust watchdog announced it had launched a probe into nine pharmaceutical companies in the country over allegations of a cartel. Report
> The animal health division of drugmaker Eli Lilly will acquire the rights to a portfolio of Pfizer products in Europe, including vaccines and feed additives, and a production facility in Sligo, Ireland. Report | Report
> Scottish start-up company, Burdica Biomed, has sealed a deal with Sinopharm, China's largest pharmaceutical and medical device distributor, that could be worth more than £70m ($106m) over the next decade. Report
> President Barack Obama ratcheted up his attacks against insurance companies in an attempt to get skittish Democrats behind his health overhaul legislation. Report
> Health Secretary Kathleen Sebelius blamed delays in passing healthcare reform on President Barack Obama having to spend "far too much time talking about what's not in the bill" and trying to counter "wild accusations" by Republicans. Report
Biotech News
@FierceBiotech: Good story here: Alnara Pharmaceuticals flourishes from Altus demise. Report | Follow @FierceBiotech
@JohnCFierce: Memo to boss: Tweeting from Europe gives me quite a jump on the news. Consider a 6 -month Paris lease. Top floor preferred, not essential. Follow @JohnCFierce
> The FDA has approved Cell Therapeutics' facility to manufacture Pixuvri (pixantrone), an experimental cancer drug which is currently under review. Report
> In a terse announcement released Friday, Santa Clara, CA-based XenoPort said it's cutting 50 percent of its 219-person staff and refocusing its development efforts on its late-stage product candidates. XenoPort article
> The Pulmonary-Allergy Drugs Advisory Committee will meet tomorrow to discuss InterMune's idiopathic pulmonary fibrosis candidate pirfenidone, a product FDA staffers expressed concern about in briefing documents. News
Biotech IT News
> Data oddities plague Russian clinical trials. Article
> Crowdsourcing may help clear up the drug lawsuit archive. Report
> Doctors' music downloads may be leaking patient data. Item
> Hosting setup hints at pre/post-market data loop. Report
> BioClinica adds heart, diagnostics savvy. Report
And Finally... Can a drug that has been used to treat malaria for years possibly be used to treat breast cancer before it becomes invasive? Report